磁共振引导自适应立体定向放疗治疗前列腺癌的前瞻性单臂2期研究:早期毒性结果
结果显示早期≥2级泌尿生殖(GU)毒性和胃肠道(GI)毒性累计最大发生率分别为23.8%和5.0%,患者报告结局证实GI毒性低,GU≥2级毒性在MRgRT结束时达峰值19.8%,3个月随访时恢复至基线平均评分。
要点
- MRgRT 5次7.25 Gy治疗前列腺癌,早期≥2级GU毒性23.8%、GI毒性5.0%。
- 未观察到早期3级GI毒性;早期3级GU毒性按CTCAE为0%、按RTOG为5.9%。
- GU≥2级毒性在治疗结束时峰值19.8%,3个月随访恢复至基线平均评分。
核心结论
- MRgRT治疗局限性前列腺癌的早期GI和GU毒性发生率低,临床医生报告和患者报告结局均一致。
主要发现
- 早期≥2级GU毒性累计最大发生率为23.8%,GI毒性为5.0%。
- 未观察到早期3级GI毒性;早期3级GU毒性按CTCAE为0%、按RTOG为5.9%,源于放射性膀胱炎分级差异。
- GU≥2级毒性在MRgRT结束时峰值19.8%,3个月随访恢复至基线平均评分。
- 患者报告结局数据证实早期GI毒性发生率低。
关键数值与推荐
- MRgRT总剂量为5次×7.25 Gy,每日自适应计划,尿道相对保护至6.5 Gy/次。
- 毒性评估采用CTCAE、RTOG、EORTC QLQ-C30、QLQ-PR25和IPSS。
临床怎么用
- MRgRT可用于局限性前列腺癌的SBRT治疗,每日自适应计划有助于减少早期GI和GU毒性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Use of stereotactic body radiation therapy (SBRT) is increasing in patients with localized prostate cancer, but concerns about early and late gastrointestinal (GI) and genitourinary (GU) toxicity exist after moderately or extremely hypofractionated radiation therapy schemes. Magnetic resonance guided radiation therapy (MRgRT) was clinically introduced in 2014. MrgRT allows for SBRT delivery with smaller uncertainty margins and permits daily adaptive planning. A phase 2 study in patients with localized prostate cancer was performed to study early GI and GU toxicity after SBRT using MRgRT. METHODS AND MATERIALS: One hundred one patients with clinical stage T1-3bN0M0 prostate cancer were enrolled in this prospective phase 2 study. All but 4 patients had intermediate- or high-risk prostate cancer, and 82.2% received adjuvant hormonal treatment. MRgRT was delivered in 5 fractions of 7.25 Gy to the target volume using daily plan adaptation with simultaneous relative sparing of the urethra to a dose of 6.5 Gy per fraction. Early toxicity was studied using both clinician- (Common Terminology Criteria for Adverse Events and Radiation Therapy Oncology Group) and patient-reported outcome measurements (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-C30, Quality of Life Questionnaire PR25, and International Prostate Symptom Scoring). RESULTS: The maximum cumulative grade ≥2 early GU and GI toxicity measured by any symptom at any study time point was 23.8% and 5.0%, respectively. No early grade 3 GI toxicity was observed. Early grade 3 GU toxicity was 0% and 5.9% according to the Common Terminology Criteria for Adverse Events and Radiation Therapy Oncology Group and scoring systems, respectively, as a result of different grading of radiation cystitis. The low incidence of early GI toxicity was confirmed by patient-reported outcome data. GU grade ≥2 toxicity peaked to 19.8% at the end of MRgRT, followed by a return to the baseline average score at 3-month follow-up. CONCLUSIONS: This prospective study of MRgRT in patients with localized prostate cancer observed a low incidence of early GI and GU toxicity, both in clinician- and patient-reported outcome measurements.
引用
- Bruynzeel AME, Tetar SU, Oei SS, et al. A Prospective Single-Arm Phase 2 Study of Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy for Prostate Cancer: Early Toxicity Results. Int J Radiat Oncol Biol Phys. 2019. PMID: 31419510. doi:10.1016/j.ijrobp.2019.08.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。